What is the optimal antibiotic treatment strategy for carbapenem-resistant Acinetobacter baumannii (CRAB)? A multicentre study in Korea
- PMID: 33571708
- DOI: 10.1016/j.jgar.2021.01.018
What is the optimal antibiotic treatment strategy for carbapenem-resistant Acinetobacter baumannii (CRAB)? A multicentre study in Korea
Abstract
Objectives: The optimal treatment option for carbapenem-resistant Acinetobacter baumannii (CRAB) is still limited. This study investigated the efficacy of three or more antibiotic types and regimens for treatment of CRAB infection in high CRAB endemic areas.
Methods: A multicentre retrospective study was conducted to evaluate the efficacy of treatment types and regimens of CRAB infections in 10 tertiary hospitals in the Republic of Korea. The outcomes comprised 7-day and 28-day mortality, and clinical and microbiological responses at 7 days, 28 days, and the end of treatment. Nephrotoxicity and hepatotoxicity were evaluated as drug adverse reactions.
Results: A total of 282 patients were included in the study. Among the CRAB strains, the two most susceptible antibiotics were colistin (99.6%) and minocycline (80.4%). A combination of colistin and carbapenem significantly reduced 7-day mortality, and a sulbactam-containing regimen significantly reduced 28-day mortality. Colistin monotherapy was significantly associated with increased 7-day and 28-day mortality. A minocycline-containing regimen showed the best microbiological responses at 7 days, 28 days, and the end of treatment. Colistin and tigecycline were associated with increased nephrotoxicity and hepatotoxicity, respectively. Subgroup analysis of patients with pneumonia showed similar results to the overall CRAB infection.
Conclusions: A combination of colistin and carbapenem and sulbactam-containing regimen may contribute improved mortality in CRAB infections. Colistin monotherapy should be considered cautiously in severe CRAB infections or CRAB pneumonia. A minocycline-containing regimen showed the best microbiological responses, and further studies may be needed to evaluate improved mortality.
Keywords: Acinetobacter baumannii; Acinetobacter infections; Antibacterial agents; Combination drug therapy; Drug resistance.
Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.
Similar articles
-
Antibiotic strategies and clinical outcomes in critically ill patients with pneumonia caused by carbapenem-resistant Acinetobacter baumannii.Clin Microbiol Infect. 2018 Aug;24(8):908.e1-908.e7. doi: 10.1016/j.cmi.2017.10.033. Epub 2017 Nov 3. Clin Microbiol Infect. 2018. PMID: 29108947
-
Comparative effectiveness and safety of colistin-based versus high-dose ampicillin/sulbactam-based combination therapy for nosocomial pneumonia caused by carbapenem-resistant Acinetobacter baumannii.Antimicrob Agents Chemother. 2025 Jun 4;69(6):e0188024. doi: 10.1128/aac.01880-24. Epub 2025 Apr 23. Antimicrob Agents Chemother. 2025. PMID: 40265949 Free PMC article.
-
Intravenous fosfomycin for treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii: A multi-centre clinical experience.Int J Antimicrob Agents. 2024 Jul;64(1):107190. doi: 10.1016/j.ijantimicag.2024.107190. Epub 2024 Apr 30. Int J Antimicrob Agents. 2024. PMID: 38697579
-
Comparison of cefiderocol and colistin-based regimens for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii: a systematic review with meta-analysis and trial sequential analysis.BMC Infect Dis. 2024 Sep 13;24(1):967. doi: 10.1186/s12879-024-09899-5. BMC Infect Dis. 2024. PMID: 39271977 Free PMC article.
-
Optimum treatment strategies for carbapenem-resistant Acinetobacter baumannii bacteremia.Expert Rev Anti Infect Ther. 2015 Jun;13(6):769-77. doi: 10.1586/14787210.2015.1032254. Epub 2015 Apr 12. Expert Rev Anti Infect Ther. 2015. PMID: 25865094 Review.
Cited by
-
Clinical Effectiveness of Tetracycline-Class Agents Based Regimens in Patients With Carbapenem-Resistant Acinetobacter baumannii Bacteremia: A Single-Center Retrospective Cohort Study.J Korean Med Sci. 2023 Aug 28;38(34):e263. doi: 10.3346/jkms.2023.38.e263. J Korean Med Sci. 2023. PMID: 37644679 Free PMC article.
-
Iron-dependent mechanisms in Acinetobacter baumannii: pathogenicity and resistance.JAC Antimicrob Resist. 2025 Mar 19;7(2):dlaf039. doi: 10.1093/jacamr/dlaf039. eCollection 2025 Apr. JAC Antimicrob Resist. 2025. PMID: 40110557 Free PMC article. Review.
-
Sulbactam for carbapenem-resistant Acinetobacter baumannii infections: a literature review.JAC Antimicrob Resist. 2025 Apr 12;7(2):dlaf055. doi: 10.1093/jacamr/dlaf055. eCollection 2025 Apr. JAC Antimicrob Resist. 2025. PMID: 40224360 Free PMC article. Review.
-
Treatment of infections caused by carbapenem-resistant Acinetobacter baumannii.Front Cell Infect Microbiol. 2024 Jul 18;14:1395260. doi: 10.3389/fcimb.2024.1395260. eCollection 2024. Front Cell Infect Microbiol. 2024. PMID: 39081869 Free PMC article. Review.
-
Optimizing Treatment for Carbapenem-Resistant Acinetobacter baumannii Complex Infections: A Review of Current Evidence.Infect Chemother. 2024 Jun;56(2):171-187. doi: 10.3947/ic.2024.0055. Infect Chemother. 2024. PMID: 38960737 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical